En Carta Diagnostics
En Carta Diagnostics is a Paris-based deeptech company dedicated to democratizing access to accurate, affordable, and accessible molecular diagnostics worldwide. They develop innovative point-of-care diagnostic kits, focusing initially on early Lyme disease detection, utilizing synthetic biology technologies to create portable, rapid, and precise diagnostic tools that can be used anywhere without specialized equipment.
Industries
Nr. of Employees
small (1-50)
Products
Portable early Lyme disease molecular diagnostic kit
A cassette-format point-of-care molecular test designed to detect the causative bacterium of Lyme disease directly at the tick bite site for early detection and rapid intervention.
Field-validated Zika and Chikungunya diagnostics
Molecular diagnostic tests for Zika and Chikungunya that have been field tested on patient samples, demonstrating high accuracy and specificity compared to reference PCR protocols.
SARS-CoV-2 diagnostic kit with variant discrimination
A COVID-19 diagnostic kit optimized for simple extraction workflows that can process batches (e.g., results for 100 tests in under an hour) and distinguish major viral variants via nucleotide-resolution detection.
Under-development duplex Chlamydia/Gonorrhea home screening test
A duplex molecular diagnostic intended for at-home screening of Chlamydia and Gonorrhea with a target time-to-result under 30 minutes.
EC Pocket Lyme test
A rapid, Point-of-Need molecular diagnostic test for the early-stage detection of Borrelia bacteria, the cause of Lyme disease.
Early diagnosis of Lyme disease
A portable Lyme diagnostic that allows for the detection of the bacterium responsible for Lyme disease right after a tick bite, directly on the bite site.
Portable early Lyme disease molecular diagnostic kit
A cassette-format point-of-care molecular test designed to detect the causative bacterium of Lyme disease directly at the tick bite site for early detection and rapid intervention.
Field-validated Zika and Chikungunya diagnostics
Molecular diagnostic tests for Zika and Chikungunya that have been field tested on patient samples, demonstrating high accuracy and specificity compared to reference PCR protocols.
SARS-CoV-2 diagnostic kit with variant discrimination
A COVID-19 diagnostic kit optimized for simple extraction workflows that can process batches (e.g., results for 100 tests in under an hour) and distinguish major viral variants via nucleotide-resolution detection.
Under-development duplex Chlamydia/Gonorrhea home screening test
A duplex molecular diagnostic intended for at-home screening of Chlamydia and Gonorrhea with a target time-to-result under 30 minutes.
EC Pocket Lyme test
A rapid, Point-of-Need molecular diagnostic test for the early-stage detection of Borrelia bacteria, the cause of Lyme disease.
Early diagnosis of Lyme disease
A portable Lyme diagnostic that allows for the detection of the bacterium responsible for Lyme disease right after a tick bite, directly on the bite site.
Services
Contract development of programmable molecular diagnostics with minimal configuration; fast prototyping to target-specific nucleic acid sequences and sample-processing customization.
Contract development of programmable molecular diagnostics with minimal configuration; fast prototyping to target-specific nucleic acid sequences and sample-processing customization.
Expertise Areas
- Point-of-care molecular diagnostics
- Synthetic biology-based assay design
- Paper-based reagent formulation and stabilization
- Field clinical validation and trial execution
Key Technologies
- Synthetic biology
- Toehold-switch-inspired RNA/DNA sensors
- Paper-based lyophilized diagnostics
- Single-temperature isothermal molecular assays
News & Updates
Funding led by Centrale Supélec Venture to develop Lyme disease diagnostic kit.
Sharing the company's mission and vision in front of entrepreneurs and investors.
Secured a $17.7 million collaboration agreement for the SPITFIRE project.
Won a USD 25,000 prize for their technology.
Selected to be part of the WILCO innovation accelerator for biotech and smart pharma.
Funding led by Centrale Supélec Venture to develop Lyme disease diagnostic kit.
Sharing the company's mission and vision in front of entrepreneurs and investors.
Secured a $17.7 million collaboration agreement for the SPITFIRE project.
Won a USD 25,000 prize for their technology.
Selected to be part of the WILCO innovation accelerator for biotech and smart pharma.